CL2011003154A1 - Compuestos derivados de pirazinooxazepina, activador del receptor de serotonina 5-ht2c, composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis de sintomas del aparato urinario inferior, obesidad y/o prolapso de organos. - Google Patents

Compuestos derivados de pirazinooxazepina, activador del receptor de serotonina 5-ht2c, composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis de sintomas del aparato urinario inferior, obesidad y/o prolapso de organos.

Info

Publication number
CL2011003154A1
CL2011003154A1 CL2011003154A CL2011003154A CL2011003154A1 CL 2011003154 A1 CL2011003154 A1 CL 2011003154A1 CL 2011003154 A CL2011003154 A CL 2011003154A CL 2011003154 A CL2011003154 A CL 2011003154A CL 2011003154 A1 CL2011003154 A1 CL 2011003154A1
Authority
CL
Chile
Prior art keywords
obesity
treatment
pharmaceutical composition
ht2c
pyrazinooxazepine
Prior art date
Application number
CL2011003154A
Other languages
English (en)
Inventor
Shigekazu Sasaki
Tomokazu Kusumoto
Izumi Nomura
Hironobu Maezaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2011003154A1 publication Critical patent/CL2011003154A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE PROPORCIONA UN COMPUESTO QUE TIENE UNA ACCIÓN ACTIVADORA DEL RECEPTOR DE 5-HT2C DE SEROTONINA. UN COMPUESTO REPRESENTADO POR LA FÓRMULA (LO): EN DONDE CADA SÍMBOLO ES COMO SE DEFINIÓ EN LA MEMORIA DESCRIPTIVA O UNA DE SUS SALES. COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE; Y SU USO EN EL TRATAMIENTO Y/O POFILAXIS DE SÍNTOMAS DEL APARATO URINARIO INFERIOR, OBESIDAD Y/O PROLAPSO DE ÓRGANOS.
CL2011003154A 2009-06-15 2011-12-14 Compuestos derivados de pirazinooxazepina, activador del receptor de serotonina 5-ht2c, composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis de sintomas del aparato urinario inferior, obesidad y/o prolapso de organos. CL2011003154A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009142673 2009-06-15

Publications (1)

Publication Number Publication Date
CL2011003154A1 true CL2011003154A1 (es) 2012-06-15

Family

ID=42561089

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003154A CL2011003154A1 (es) 2009-06-15 2011-12-14 Compuestos derivados de pirazinooxazepina, activador del receptor de serotonina 5-ht2c, composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis de sintomas del aparato urinario inferior, obesidad y/o prolapso de organos.

Country Status (41)

Country Link
US (4) US8318722B2 (es)
EP (1) EP2442870B1 (es)
JP (2) JP5579262B2 (es)
KR (1) KR101768234B1 (es)
CN (1) CN102458579B (es)
AR (1) AR077094A1 (es)
AU (1) AU2010260847B2 (es)
BR (1) BRPI1011502A2 (es)
CA (1) CA2765239C (es)
CL (1) CL2011003154A1 (es)
CO (1) CO6491037A2 (es)
CR (1) CR20120021A (es)
CY (1) CY1115483T1 (es)
DK (1) DK2442870T3 (es)
DO (1) DOP2011000393A (es)
EA (1) EA021079B1 (es)
EC (1) ECSP12011603A (es)
ES (1) ES2480275T3 (es)
GE (1) GEP20146168B (es)
HK (1) HK1169623A1 (es)
HR (1) HRP20140589T1 (es)
IL (1) IL216761A (es)
JO (1) JO3087B1 (es)
MA (1) MA33430B1 (es)
ME (1) ME01835B (es)
MX (1) MX2011013081A (es)
MY (1) MY157497A (es)
NZ (1) NZ597507A (es)
PE (1) PE20121049A1 (es)
PL (1) PL2442870T3 (es)
PT (1) PT2442870E (es)
RS (1) RS53414B (es)
SG (1) SG176696A1 (es)
SI (1) SI2442870T1 (es)
SM (1) SMT201400080B (es)
TN (1) TN2011000630A1 (es)
TW (2) TW201529584A (es)
UA (1) UA108357C2 (es)
UY (1) UY32707A (es)
WO (1) WO2010147226A1 (es)
ZA (1) ZA201109370B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158617B2 (en) * 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
BRPI1011502A2 (pt) * 2009-06-15 2016-03-22 Takeda Pharmaceutical composto, pró-droga, medicamento, método para a profilaxia ou tratamento de um sintoma do trato urinário inferior, obesidade, e/ou prolapso de órgão em um mamífero, e, uso do composto.
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
JP2014201578A (ja) * 2013-04-09 2014-10-27 武田薬品工業株式会社 線維筋痛症治療剤
JP2014214132A (ja) * 2013-04-26 2014-11-17 武田薬品工業株式会社 ニコチン依存症の予防・治療剤
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2017026538A1 (en) 2015-08-07 2017-02-16 Takeda Pharmaceutical Company Limited Production method of pyrazine
TW201729814A (zh) 2015-12-24 2017-09-01 武田藥品工業股份有限公司 固形製劑
US9985579B2 (en) 2016-04-12 2018-05-29 Preformed Line Products Co. Mounting assembly for mounting a solar panel
EP3733204A4 (en) * 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
ES2328671T3 (es) 2000-11-20 2009-11-17 Biovitrum Ab (Publ) Compuestos de piperazilpirazinas como antagonistas del receptor de serotonina 5-ht2.
AU2002314744A1 (en) 2001-04-17 2002-10-28 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
CN100484933C (zh) 2002-06-19 2009-05-06 比奥维特罗姆股份公开公司 新的吡嗪化合物及其在制备用于治疗与5-羟色胺相关的疾病的药物中的用途
CA2485532C (en) 2002-06-19 2012-03-06 Biovitrum Ab Process for the preparation of 2-methyl piperazine derivatives
CA2514547A1 (en) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited Receptor agonists
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
EA016558B1 (ru) * 2003-06-17 2012-05-30 Арена Фармасьютикалз, Инк. Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
MXPA05013364A (es) * 2003-06-17 2006-03-17 Arena Pharm Inc Procedimiento para preparar 3-benzazepinas.
JP2006056881A (ja) 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
ATE437859T1 (de) 2005-09-01 2009-08-15 Lilly Co Eli 6-substituierte- 2,3,4,5-tetrahydro-1h- benzoädüazepine als 5-ht2c-rezeptoragonisten
FR2895259B1 (fr) 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
US8158617B2 (en) * 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
EP2123644B1 (en) * 2007-03-07 2014-12-17 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
WO2009032754A2 (en) 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
WO2009063993A1 (ja) * 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
JP5361733B2 (ja) * 2007-11-15 2013-12-04 武田薬品工業株式会社 ピリドオキサゼピン誘導体およびその用途
BRPI1011502A2 (pt) * 2009-06-15 2016-03-22 Takeda Pharmaceutical composto, pró-droga, medicamento, método para a profilaxia ou tratamento de um sintoma do trato urinário inferior, obesidade, e/ou prolapso de órgão em um mamífero, e, uso do composto.
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor

Also Published As

Publication number Publication date
HRP20140589T1 (hr) 2014-08-01
US8318722B2 (en) 2012-11-27
EP2442870B1 (en) 2014-04-16
IL216761A0 (en) 2012-02-29
UA108357C2 (xx) 2015-04-27
ECSP12011603A (es) 2012-03-30
US20110288291A1 (en) 2011-11-24
CR20120021A (es) 2012-03-06
EA201270017A1 (ru) 2012-07-30
JP2012107032A (ja) 2012-06-07
US20110282054A1 (en) 2011-11-17
CN102458579B (zh) 2014-11-05
SI2442870T1 (sl) 2014-07-31
NZ597507A (en) 2013-09-27
AU2010260847B2 (en) 2016-11-24
MX2011013081A (es) 2012-01-20
PE20121049A1 (es) 2012-08-22
US8314088B2 (en) 2012-11-20
US9115139B2 (en) 2015-08-25
WO2010147226A1 (en) 2010-12-23
US20100317651A1 (en) 2010-12-16
EP2442870A1 (en) 2012-04-25
GEP20146168B (en) 2014-09-25
CA2765239C (en) 2018-08-07
CN102458579A (zh) 2012-05-16
TWI542592B (zh) 2016-07-21
TW201109338A (en) 2011-03-16
RS53414B (en) 2014-12-31
SMT201400080B (it) 2014-09-08
ME01835B (me) 2014-12-20
IL216761A (en) 2016-03-31
US20120135979A1 (en) 2012-05-31
AU2010260847A1 (en) 2012-01-19
CY1115483T1 (el) 2017-01-04
KR101768234B1 (ko) 2017-08-14
ES2480275T3 (es) 2014-07-25
JP5579262B2 (ja) 2014-08-27
ZA201109370B (en) 2012-10-31
TN2011000630A1 (en) 2013-05-24
UY32707A (es) 2011-01-31
US8324201B2 (en) 2012-12-04
MA33430B1 (fr) 2012-07-03
BRPI1011502A2 (pt) 2016-03-22
JO3087B1 (ar) 2017-03-15
KR20120034734A (ko) 2012-04-12
HK1169623A1 (en) 2013-02-01
JP5579203B2 (ja) 2014-08-27
CO6491037A2 (es) 2012-07-31
MY157497A (en) 2016-06-15
PT2442870E (pt) 2014-07-16
SG176696A1 (en) 2012-01-30
PL2442870T3 (pl) 2014-12-31
AR077094A1 (es) 2011-08-03
DOP2011000393A (es) 2012-02-15
JP2012530051A (ja) 2012-11-29
DK2442870T3 (da) 2014-06-30
EA021079B1 (ru) 2015-03-31
CA2765239A1 (en) 2010-12-23
TW201529584A (zh) 2015-08-01

Similar Documents

Publication Publication Date Title
CL2011003154A1 (es) Compuestos derivados de pirazinooxazepina, activador del receptor de serotonina 5-ht2c, composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis de sintomas del aparato urinario inferior, obesidad y/o prolapso de organos.
DOP2010000267A (es) Compuesto heterociclico
DOP2013000030A (es) Compuesto heterociclico y su uso
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CO6751239A2 (es) Compuesto bicíclico
CR20110100A (es) Nuevos derivados de sulfamida sustituida
ECSP099330A (es) Compuesto de indol
DOP2012000006A (es) Agonista de gpr119
PE20121555A1 (es) COMBINACION DE UN AGENTE INDUCTOR DE POLIPLOIDIA Y UN INHIBIDOR Bcl-2
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
CO6260091A2 (es) Derivados de iminopiridina y su uso
ECSP11011294A (es) Compuestos de anillo fusionados y su uso
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
CL2009000116A1 (es) Compuestos derivados de heterotriciclos sustituidos, antagonistas del receptor crf; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento de trastornos afectivos, depresion, ansiedad y sindrome del colon irritable.
NI201000036A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
UY32131A (es) Compuestos de anillo fusionado y uso de los mismos
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
CU20100063A7 (es) Benzotiazoles como moduladores del receptor de grelina
ES2572368T3 (es) Tratamiento de la artrosis
UY32042A (es) Compuestos de 2-aminopirimidina como potentes inhibidores de hsp-90
CL2012003539A1 (es) Compuestos derivados de alquil-piperazino-fenil 4(3h)ona; composicion farmaceutica y su uso para el tratamiento de los trastornos asociados a los receptores serotoninergicos 5-ht1a y 5-ht2a, tales como depresion, ansiedad, y trastornos del sueño.